DekaBank Deutsche Girozentrale Sells 2,423 Shares of Repligen Co. (NASDAQ:RGEN)

DekaBank Deutsche Girozentrale decreased its holdings in Repligen Co. (NASDAQ:RGEN) by 23.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,034 shares of the biotechnology company’s stock after selling 2,423 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Repligen were worth $1,475,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Parnassus Investments LLC bought a new stake in Repligen in the third quarter worth about $87,475,000. Norges Bank bought a new stake in Repligen in the fourth quarter worth about $76,155,000. Alliancebernstein L.P. lifted its stake in Repligen by 32.9% in the fourth quarter. Alliancebernstein L.P. now owns 1,079,105 shares of the biotechnology company’s stock worth $182,703,000 after purchasing an additional 267,436 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in Repligen in the third quarter worth about $41,540,000. Finally, Riverbridge Partners LLC lifted its stake in Repligen by 94.5% in the third quarter. Riverbridge Partners LLC now owns 417,756 shares of the biotechnology company’s stock worth $66,427,000 after purchasing an additional 202,960 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Performance

Shares of RGEN stock opened at $171.53 on Monday. The firm has a market cap of $9.58 billion, a price-to-earnings ratio of 238.24, a PEG ratio of 5.62 and a beta of 1.02. The company’s 50 day moving average is $192.16 and its 200 day moving average is $173.21. The company has a quick ratio of 5.75, a current ratio of 7.02 and a debt-to-equity ratio of 0.26. Repligen Co. has a 52-week low of $110.45 and a 52-week high of $211.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.33. The company had revenue of $155.74 million for the quarter, compared to analyst estimates of $155.38 million. Repligen had a net margin of 6.51% and a return on equity of 5.00%. Repligen’s revenue was down 16.6% compared to the same quarter last year. During the same period last year, the company posted $0.68 earnings per share. On average, sell-side analysts anticipate that Repligen Co. will post 1.46 EPS for the current fiscal year.

Insider Activity at Repligen

In related news, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the transaction, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at $36,575,562.56. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Repligen news, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction on Friday, March 8th. The shares were sold at an average price of $197.44, for a total value of $3,298,630.08. Following the transaction, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at $36,575,562.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO James Bylund sold 4,373 shares of Repligen stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the transaction, the chief operating officer now directly owns 14,135 shares in the company, valued at $2,799,860.80. The disclosure for this sale can be found here. Insiders have sold a total of 25,597 shares of company stock valued at $5,039,532 over the last ninety days. 1.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on RGEN. KeyCorp raised their price objective on shares of Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. JPMorgan Chase & Co. lifted their price target on shares of Repligen from $170.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, December 20th. Finally, Stifel Nicolaus lifted their price target on shares of Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and an average price target of $196.70.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.